Member Info for Elonmusky99

I hope he gets on his bus OK ;)

Just topped again - amazing price - you'll be crying in your frosties when we're 48p ;)

20-Sep-24 09:29:00 10.34 87,623 Buy* 10.00 10.50 9,060

Do you add speed to your frosties???

We're talking about pennies at the moment which is immaterial - so the daily graph will be up and down

my broker advised me on 48p in the next 12 months so if you've got spare funds now is a great time to top-up

....analyst predicts that the share price of Skinbiotherapeutics PLC (SBTX:LSE) will increase to 48.00 in the next year,

Do you actually own any shares in sbtx?? when they rise to circa 20p I'll send you gonzo in the post

.. don't worry chaps - this wouldn't have happened if the commercials were not there:

as we all know - this is the key relationship to commercial success...

appointment of Dr Surinder 'Dass' Chahal as Cosmetic Science / Customer Alliances Advisor to the Board.

hold on... starships were meant to fly

Someone stop giving that man double espresso shots..

anyone who has been here before with SBTX knows it's a roller coaster ride for share holders..

as long as you buy in cheap - circa less than 15p you will double your investment but you may have to wait up to 18 months to see this happen

the board is not the most dynamic I've ever seen so it's very much stop/start approach.. I believe the science (if it can be commercialised properly) - not just amazon channels which is a joke - could be a world leader in its field

it's now gamble time for new and current investors - I've bought another 50k today so I'm in.. let's hope the commercial pipeline via Croda is robust and isn't just hype.. clinical trials are one thing - getting commercial is another skill...

If everyone stopped selling and let the SP slightly increase it might do wonders for the market sentiment (without RNS update)

OK.. let's see...

this was 28th June 2024.. where's your RNS update stating this information please for your optional route fundraising

either way.. it's still fundraising and not revenue generating.

ALSO, please note on Amazon the sales for the product.. they actually tell you (50 sold last month).. not sure they will pay for the cleaners ;)

OK.. let's see...

..... 20 June 2024 from Macquarie for £100,000 of Convertible Bonds from the £5.0 million convertible bond facility announced on 25 January 2024. The Company has drawn a total of £1,600,000 under the Facility..

that still allows for circa 3.4m to be drawn and pay for those lunches at the Ivy... could keep this rolling for ages....

just bank rolling the board.. I wish my job wasn't based on performance - bonuses all round me thinks

Hehe.. that will kill any chance.. he's got less ability than mystic meg.. possibly mystic mog

Agree... something has to change to drive the SP back to where it should be; silence on the RNS creates panic selling and distrust from all involved.. if you're paid to do a job then you need to perform - internal change is needed in my humble opinion - it's all a bit Gareth Southgate (keep the plan devised 3 years ago and hope for the best - no reaction or decisive strategic move.. I suspect if their positions were up for votes they wouldn't still be there possibly (the Rishi syndrome - trying to appease everyone and not have the courage to drive forward)

Very true.. I just feel they need a truly commercial sales director to push these potential pipelines through. Having a great product is an excellent start but you need excellent swordsmanship to keep the commercials on track. Not sure they have quality within the existing team. They rely heavily on 3rd party agencies to drive this forward.. you need this quality internal. I agree - we might here another RNS to finance more outgoings and current salaries. Current revenues can't support this activity.

I'm not trolling by-the-way - I have a major stake in SBTX which I bought from the launch (due to success of OPti). I'm simply suggesting it needs specialists on the board to drive the commercial pipeline. Having a good product simply isn't good enough. You need vision and drive (and RNS updates)... silence doesn't help anyone simply drives the SP down...

I bought into the Opti hype years ago and I was luckily enough to buy in at 15p and sold for £1+. I decided to bail out because the commercial pipelines simply weren't in place for the market hype. Opti is now trading at circa 15p... and nothing has really changed in years. The same old story being spun. Unfortunately SH bought in late and have lost fortunes...

SBTX is no different to OPti... exactly the same principle.. hype the market - make a big splash and then slowly decline the SP and sell off more shares to keep going. I bought in when it was first launched so I've still lost my investment but there are so many SH who once again have lost thousands.. if not their shirts..

The type of companies are all the same.. buy in early (be willing to take the gamble) and sell on when you've decided you've made a decent profit.

SBTX is still talking about commercial pipelines/etc but they don't have the board members to make this happen. I hope the SP does rise but it's worth noting it was once worth 71p... without commercial revenues.

There comes a time when real revenues outweigh the hype....

JMO

SkinBioTherapeutics, a company dedicated to skin health, has announced the conversion of £100,000 in convertible bonds into over 1.1 million ordinary shares, following a notice from Macquarie. These new shares are to be admitted to AIM, raising the company’s total issued shares and voting rights to 203,372,037. This strategic financial move is part of the company’s ongoing efforts to advance its skin healthcare technology and product offerings, including a supplement for psoriasis.

B doesn't stand for billions.. those are the actual figures we are dealing with - without all this emotion and rallying.. the current SP should be circa 5p.. so actually holding up even though financials/commercials and share dilution to raise capital and use it for payroll and those expensive coffee machines...

SkinBioTherapeutics had very high historical volatility over the last 90 days

SkinBioTherapeutics has high likelihood to experience some financial distress in the next 2 years

The company reported the revenue of 132.06 K. Net Loss for the year was (2.84 M) with profit before overhead, payroll, taxes, and interest of 45.34 K.

SkinBioTherapeutics generates negative cash flow from operations

About 20.0% of the company outstanding shares are owned by corporate insiders

Fundamentals SkinBioTherapeutics Peer Average

Return On Equity -1.19 -0.31

Return On Asset -0.61 -0.14

Operating Margin (13.01) % (5.51) %

Current Valuation 14.87 M 16.62 B

Shares Outstanding 202.26 M 571.82 M

Shares Owned By Insiders 19.57 % 10.09 %

Shares Owned By Institutions 18.59 % 39.21 %

Price To Book 5.35 X 9.51 X

Price To Sales 120.86 X 11.42 X

Revenue 132.06 K 9.43 B

Gross Profit 45.34 K 27.38 B

EBITDA (2.96 M) 3.9 B

Net Income (2.84 M) 570.98 M

Total Debt 100.65 K 5.32 B

Book Value Per Share 0.02 X 1.93 K

Cash Flow From Operations (2.65 M) 971.22 M

Earnings Per Share (0.02) X 3.12 X

Target Price 48.0

Number Of Employees 11 18.84 K

Beta 1.67 -0.15

Market Capitalization 18.71 M 19.03 B

Total Asset 2.59 M 29.47 B

Retained Earnings (11.12 M) 9.33 B

Working Capital 1.19 M 1.48 B

Net Asset 2.59 M

Critical to any company's success is the EBITDA - currently £2.4m loss at EBITDA